T-Cell Engagers: Signal 1 Without Signal 2

A T-cell engager does not give the T cell an instruction. It gives it an address. A bispecific antibody with one arm on CD3 and the other on a tumour antigen forces two membranes into contact and lets the immunological synapse assemble itself. That is signal 1 delivered by geometry — no peptide processed, no MHC required, and the T cell's own specificity irrelevant. Every characteristic of this drug class follows from one asymmetry: it delivers signal 1 and does not deliver signal 2. It works where MHC-I has been lost, it needs no per-patient manufacturing, and it drives cytokine release and exhaustion far more readily than a physiological antigen encounter ever would. The interesting variable is rarely affinity. It is how many receptors get crosslinked, on which cell, for how long.

The two arms of an engager, the costimulation and adhesion machinery that has to be supplied or borrowed, the killing output, and the cytokine-release and resistance layers that scale with crosslinking rather than dose. Open the interactive version to click any protein for its role and the matching validated reagent.

Why proximity is enough

Crosslinking CD3 on a T cell to a surface antigen on a target cell is sufficient to build a functional synapse and trigger killing. Nothing needs to be processed and presented, and the T cell's own T-cell receptor never sees its cognate peptide. That is the point: the entire polyclonal repertoire becomes available against a single antigen, and the commonest route of escape from both checkpoint blockade and TCR-engineered cells — loss of MHC class I — does not protect the tumour at all. The trade is that a small bispecific has a short serum half-life and must be infused continuously or re-dosed frequently, and that everything downstream is shaped by dose rather than regulated physiologically.

The antigen arm is where the therapeutic index is actually set, and the map deliberately shows eight of them side by side. CD19 and CD20 are the mature B-cell targets where the class was proven; BCMA carries it into myeloma; CD33 into myeloid disease; and EpCAM, EGFR, HER2 and CEA into solid tumours, where the problem changes character. On-target off-tumour toxicity is the limiting factor for every one of the solid-tumour antigens, because none of them is truly tumour-restricted: EpCAM is on normal epithelium, EGFR on skin and gut, CEA on colonic mucosa. The engager cannot tell the difference. Antigen density, not antigen presence, is what has to separate the tumour from the tissue, and that is why affinity de-tuning — deliberately weakening the tumour arm so that killing requires high receptor density — has become a standard design move.

Signal 1 without signal 2

A conventional antigen encounter delivers T-cell receptor engagement and CD28 costimulation from CD80 and CD86 on a professional antigen-presenting cell. An engager delivers only the first. T cells activated this way proliferate and kill perfectly well in the short term, but they differentiate towards exhaustion faster and are more prone to anergy on re-challenge. This is not a subtlety; it is the central pharmacological weakness of the class, and it is the explicit rationale for the trispecific and costimulatory-engager designs now in trials, which add a CD28 or ICOS arm precisely to restore the missing signal.

It also tells you what to measure. CD25 and CD69 tell you the cells were engaged. PD-1, LAG-3, TIGIT and CTLA-4 tell you what that engagement cost. Reporting the first set without the second is how a compound looks excellent in a 24-hour cytotoxicity assay and disappoints in a repeat-dosing model. The PD-L1 arm matters here too: engager-driven IFN-γ induces PD-L1 on the tumour within hours, so the drug installs its own brake. That interaction is the basis for engager-plus-checkpoint combinations, and it is measurable in a plate.

The synapse still has to be built

Adhesion is not incidental in this system. LFA-1 (CD11a paired with CD18) binding ICAM-1 stabilises the contact long enough for granule polarisation to complete, and CD2 engaging CD58 lowers the antigen density needed for killing. That second detail has become clinically important: loss of CD58 on lymphoma cells is an emerging resistance mechanism against CD20 engagers, and it is invisible to any assay that only looks at target-antigen expression. If you are troubleshooting an engager that binds well and kills poorly, the adhesion axis is where to look before you revisit affinity.

Killing itself runs the ordinary way. Granzyme B and perforin are released from lytic granules, with CD107a surfacing as the degranulation readout, and IFN-γ and TNF as the soluble output. Both CD4 and CD8α T cells are recruited, which is worth noting: CD4 cells contribute a substantial share of the cytokine and comparatively little of the cytotoxicity, so the CD4:CD8 ratio in the product or the patient shifts the efficacy-to-toxicity balance directly.

Cytokine release syndrome is a geometry problem, not a dose problem

The cytokine that dominates the clinical picture is IL-6, and it does not come from the T cell. It comes mostly from monocytes and macrophages reacting to T-cell-derived TNF, IFN-γ and GM-CSF. That indirection is the whole explanation for the management of the syndrome: tocilizumab works because IL-6 is a downstream amplifier rather than the initiating signal, anti-GM-CSF is being tested as an upstream alternative for the same reason, CRP tracks severity because it is an IL-6-driven hepatic response, and IL-10 rises late as counter-regulation. IL-1β contributes to the neurotoxicity arm specifically, which is why anakinra behaves differently from tocilizumab in ICANS.

The key quantitative point is that the syndrome scales with how much crosslinking happens simultaneously, not with total exposure. That is why step-up dosing works at all: the same cumulative dose given in escalating fractions produces a fraction of the cytokine, because the first small dose removes most of the available target cells before the full dose arrives. It is also why IL-2, CD25 and the activation markers are worth measuring on a time course rather than at a single endpoint — the peak is early and narrow, and a 48-hour readout will miss it.

An assay checklist

The In Vivo angle

This is the deepest functional-grade layer in the pathway library: 24 of the 37 nodes on the interactive map carry an In Vivo antibody — low or ultra-low endotoxin, formulated for administration rather than staining. Both engager arms (CD3 together with CD19, CD20, EpCAM or EGFR), the whole costimulation set, the entire adhesion axis, every checkpoint on the map, and the CRS mediators TNF, GM-CSF and IL-2 are all covered. Endotoxin control is not optional in this particular assay, and the reason is specific rather than general: contaminating LPS drives monocyte IL-6 directly, so a research-grade blocking antibody will manufacture the exact readout you are trying to measure. IL-12 is on the map for the same reason — it is the clearest marker that myeloid cells in the well have been activated by something other than the engager.

The one-line version

An engager supplies proximity and nothing else. Everything that makes the class effective follows from that, and so does everything that makes it toxic. Design the experiment around crosslinking density, run it with monocytes present, and read the checkpoints as well as the kill.

For the CD19/CD20 depletion setting these molecules compete with, see B-cell depletion and the BAFF–APRIL axis; for the exhaustion programme they accelerate, see co-inhibitory checkpoints and T-cell exhaustion; and for the synthetic-receptor alternative, see CAR-T cell signalling.

For research use only. Not for use in diagnostic or therapeutic procedures.